Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863926 | 0.87 | CYP2C19 (0.32) | CYP2C19MAPK1 | |
| Ethylene Glycol SCHEMBL8401119 | 0.87 | MAPK1 (0.36) | CYP2C19MAPK1ALDH1A1 | |
| SCHEMBL24654329 | 0.83 | — | — | |
| SCHEMBL7918366 | 0.77 | CYP2C19 (0.38) | CYP2C19TSHRTDP1 | |
| SCHEMBL12433234 | 0.77 | MAPK1 (0.36) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL754497 | 0.77 | MAPK1 (0.36) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL6176534 | 0.75 | MAPK1 (0.40) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL12744839 | 0.74 | CYP2C19 (0.32) | CYP2C19MAPK1 | |
| SCHEMBL19655069 | 0.74 | ALDH1A1 (0.33) | MAPK1ALDH1A1 | |
| SCHEMBL19543101 | 0.74 | ALDH1A1 (0.33) | MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577185-B2 | Solvent drying solution and processes therfor | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2026-03-17 | — | — | US | disclosed |
| US-20240262772-A1 | A SOLVENT DRYING SOLUTION AND PROCESSES THERFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-08-08 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | BGI SHENZHEN (CN) | 2024-06-27 | — | — | US | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11827661-B2 | Water soluble fluorescent or colored dyes comprising conjugating groups | Sony Group Corporation (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070054837-A1 | Bicyclic lactones, perfumery uses thereof, processes for preparing same and intermediates therefor | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| US-7169747-B2 | Bicyclic lactones, perfumery uses thereof, processes for preparing same and intermediates therefor | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| EP-0284005-B1 | METHOD OF PRODUCTION OF POLYOLEFINS | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4981930-A | POLYMERIZATION CATALYSTS | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0284005-A2 | Method of production of polyolefins | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | NT5C3B, NT5E, NUDT1 | CYP2C19 1338/4885MAPK1 1810/4885ALDH1A1 1433/4885 |
| US-12577185-B2 | Solvent drying solution and processes therfor | CASP7, CERT1, CA7 | CYP2C19 4500/4885MAPK1 532/4885ALDH1A1 2584/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | CYP2C19 2871/4885MAPK1 2099/4885ALDH1A1 3778/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CYP2C19 388/4885MAPK1 4830/4885ALDH1A1 135/4885 |
| US-20240262772-A1 | A SOLVENT DRYING SOLUTION AND PROCESSES THERFOR | AQP1, WFS1, AQP4 | CYP2C19 4661/4885MAPK1 2020/4885ALDH1A1 3913/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | CYP2C19 4466/4885MAPK1 4831/4885ALDH1A1 2867/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | CYP2C19 42/4885MAPK1 2111/4885ALDH1A1 10/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | CYP2C19 3783/4885MAPK1 3935/4885ALDH1A1 940/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | CYP2C19 4642/4885MAPK1 1440/4885ALDH1A1 1091/4885 |
| US-11827661-B2 | Water soluble fluorescent or colored dyes comprising conjugating groups | CHRM1, CHRM2, H1-0 | CYP2C19 4449/4885MAPK1 1966/4885ALDH1A1 965/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | CYP2C19 2517/4885MAPK1 1428/4885ALDH1A1 3842/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | CYP2C19 2675/4885MAPK1 3816/4885ALDH1A1 4502/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | CYP2C19 118/4885MAPK1 4148/4885ALDH1A1 684/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | CYP2C19 889/4885MAPK1 3335/4885ALDH1A1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.